ABSTRACT
A phase II prospective study was performed in order to evaluate how feasible and active a short, dose-intensity chemotherapy regimen and radiotherapy (Stanford V) plus highly active antiretroviral therapy (HAART) and granulocyte colony-stimulating factor (G-CSF) support is in patients with Hodgkin's disease and HIV infection. Fifty-nine patients were enrolled. Stanford V was well tolerated and 69% of the patients completed treatment with no dose reduction or delayed chemotherapy administration. The most important dose-limiting side effects were bone marrow toxicity and neurotoxicity.
Eighty-one percent of the patients achieved complete remission and after a median follow-up of 17 months 33/59 (56%) patients are alive and disease-free. The estimated 3-year overall survival (OS), disease-free survival (DFS) and freedom from progression (FFP) were 51%, 68% and 60%, respectively. Probability FFP was significantly (p=0.02) higher among patients with an international prognostic score (IPS) of 2 than in those with IPS > 2, and the percentage of FFP at two years were 83% and 41% respectively. Similarly, probability OS was significant different (p=0.0004), and the percentage of survival at three years were 76% and 33% respectively for IPS 2 and IPS>2.
Our data confirm Stanford V regimen with concomitant HAART is feasible and active in an HIV setting. However, a more intensive approach should be considered in patients with high IPS.
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INTRODUCTION
Hodgkin's disease is the most common non-AIDS-defining tumor occurring in patients with HIV infection (HD-HIV) (1) (2) (3) . All assessable data document an usually aggressive behavior of HD-HIV as compared with HD outside the HIV setting, including higher frequency of unfavorable histological subtypes such as mixed cellularity and lymphocyte depletion, advanced stage at presentation and poor treatment outcome. Bone marrow involvement has been described in 40-50% of the patients besides unusual sites of extranodal involvement (4-6).
The optimal therapeutic approach for these patients is still unknown even because of the little experience with this setting; however, it is clear that with-an-intent-to-cure chemotherapy and/or radiotherapy should be assessed in all patients with HD-HIV. Only three phase II prospective studies have been published showing a short median overall survival (OS) ranging from 11 to 18 months, despite a relatively good overall response rate (62-91%). The cause for such an unfavorable outcome may be both the underlying HIV infection and the short disease-free survival (DFS), which, in turn, may be due to antineoplastic therapy being less effective than in the general population (7-9).
Both our first two prospective studies were carried out before highly active antiretroviral therapy (HAART) was introduced into clinical practice. In 1989, when toxicity of chemotherapy and prednisone in HIV setting was a main concern, we treated 17 patients with HD-HIV using the relatively low toxic EBV (epirubicin, bleomycin and vinblastine) regimen in combination with zidovudine, the only effective anti-HIV drug available at that time. This approach yielded a 53% complete remission (CR) rate with median OS of 11 months and a 55% 2-year DFS rate (7) . Then in 1993, in an attempt to ameliorate these findings, we conducted another prospective study on the combination of the EBVP (epirubicin, vinblastine, bleomycin and prednisone) regimen with the primary use of the granulocyte colony-stimulating factor (G-CSF), which had just been introduced into clinical practice. The results of this trial on 35 patients were better and showed a CR rate of 74% with 3-year OS and DFS rates of 32% and 53%, respectively (8).
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In 1997 we took advantage of both HAART and G-CSF being available in the clinical practice and also of our improved experience in the management of patients with lymphomas and HIV-infection and designed a new approach for the patients with HD-HIV. Their outcome was still unfavorable mainly as a result of the CR and DFS rates being lower than in the general population; hence, we figured such an aggressive regimen like Stanford V, the short-term (12 weeks) intensive chemotherapy regimen with adjuvant radiotherapy developed at Stanford University for unfavorable HD in the general population (10), would be the ideal test in this group with a view to improving their poor outcome. At the same time, however, we wondered how feasible such an approach would be, which required a high intensity chemotherapy regimen and the concomitant use of HAART. The results of the phase II study with Stanford V in combination with HAART and G-CSF support in patients with HD-HIV are reported.
PATIENTS AND METHODS

INCLUSION CRITERIA
In order to be enrolled patients had to meet the following inclusion criteria: biopsy-proven HD; age > 18 years; confirmed HIV infection; clinical or pathologic stage II, III, IV according to Ann Arbor staging or stage I with adverse prognostic factors, defined as the presence of bulky disease (tumor mass > 5 cm) and/or B symptoms; no previous chemotherapy for HD; WHO performance status (PS) < 3; no concomitant or previous malignancy except for non-melanoma skin cancer and in situ cervical carcinoma; total bilirubin level < 1.5 mg/dl; creatinine level < 2.0 mg/dl; granulocyte count > 1.000 cells/dl; platelet count > 100.000 cells/dl (unless the last two findings were caused by bone marrow involvement); written informed consent. Prednisone 40 mg/m 2 was given orally every other day for 10 weeks and tapered by 10 mg every other day between weeks 10 and 12. During the whole 12-week chemotherapy cycle, patients received trimethoprim/sulfametoxazole double-strength per os once a day and fluconazole 100 mg per os every day.
G-CSF was used prophylactically at the dose of 5 mcg/kg/day from day 3 to 13 (with a pause on day 8) and from day 17 to 26 (with a pause on day 22), whereas the schedule was unchanged in the subsequent cycles.
HAART was given concomitantly since the beginning of chemotherapy, irrespectively of CD4 cell count and HIV viral load, and it was selected based on the patient's prior antiretroviral exposure.
If the granulocyte count was less than 500/dl on the day of treatment, therapy was postponed to the following week, whereas if it remained between 500 or 1.000/dl, the doses of mecloretamine, doxorubicin, vinblastine and etoposide were reduced to 75% of the full doses. The vincristine and
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Eligibility to involved field radiotherapy was possible for all patients who had achieved PR or those who were in CR and showed one or more of the following features:
1. initial bulky mediastinal disease; 2. initial, single or confluent nodal masses > 5 cm in diameter.
The total dose to initial bulky HD was 36 Gy delivered in 2 Gy fractions 5 days per week.
EVALUATION OF ANTITUMOR RESPONSE
Complete remission was defined as the complete absence of clinically detectable tumors and normalization of previously abnormal radiographic findings persisting for at least four weeks.
Partial remission (PR) was meant as an at least 50% reduction in the product of the perpendicular diameters of all tumors assessed by physical examination or radiographic check-up persisting for over one month with no new lesions occurring. Stable disease (SD) was described as a lower-than-25% change in the product of the perpendicular diameters of all tumors. Progressive disease (PD) was defined as a higher-than-25% increase in the measured lesions or the occurrence of new lesions.
EVALUATION OF TOXICITY
Toxicity was rated according to WHO criteria (12) .
STATISTICAL METHODS
Survival was calculated from the date chemotherapy was started to death from any cause or to the last time the patient showed up. DFS was calculated for patients with CR from the first CR recorded till relapse or till the last known date on which the patient was disease-free. Freedom from progression (FFP) was determined from the beginning of treatment to disease progression, relapse or last follow-up. Overall survival (OS), DFS and FFP were evaluated according to Kaplan- (13) and differences between subgroups were assessed by means of the log-rank test (14) .
Multivariate analysis of survival was performed using the Cox proportional hazards model (HR) and 95% confidence interval (CI) (15) , including all variables that were significantly associated with prognosis in the univariate analysis. Differences between qualitative parameters were performed by chi-square test (16) . In all cases, statistical significant was claimed for p 0.05 (two sides). Twenty-eight out of 59 patients (31%) showed extranodal involvement. In particular, bone marrow was involved in 24/59 patients (41%), spleen in 23/59 (39%), liver in 10/59 (17%), lung in 1/59 (2%), rectum in 1/59 (2%) and adrenal gland in 1/59 (2%). As for the histological subtype of HD, mixed cellularity was determined in 27/59 cases (46%), nodular sclerosis in 18/59 (30%), lymphocyte depletion in 4/59 (7%). In 10/59 cases (17%) the histological subtype could not be classified.
RESULTS
From
As for the distribution of the prognostic factors according to the international prognostic score (IPS) (17) , this turned out to be as follows: IPS=0 in 2/59 patients (3%), IPS=1 in 10/59 (17%), IPS=2 in 14/59 (24%), IPS=3 in 14/59 (24%), IPS=4 in 7/59 (12%), IPS=5 in 10/59 (17%) and IPS=6 in 2/59
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From (3%). In particular, 51/59 patients (86%) were males, 15/59 (25%) were 45 or older, 27/59 (46%) had stage IV disease, 33/59 (56%) had an albumin level below 4 g/dl, in 30/59 (51%) hemoglobin was < 10.5 g/dl, in 1/59 (2%) the white cell count was 15,000/dl and in 17/59 (29%) cases the lymphocytes were < 600/dl or < 8% of the white cell count. Therefore, IPS was 2 in 26/59 patients (44%) as compared to IPS >2 in the remaining 33 (56%) ( Table 2) .
Pre-treatment immunological characteristics and HIV status are shown in table 3. According to the epidemiology of HIV infection in Italy, the majority of our patients (29/59, 48%) were intravenous drug users. Seventeen out of 59 (29%) were male homosexuals and 13/59 (23%) reported heterosexual relationships as the only risk factor for HIV infection. Twelve out of 59 patients (20%) had been diagnosed AIDS before HD (Pneumocystis Carinii pneumonia (PCP) in five cases, esophageal candidiasis in four cases, disseminated tuberculosis in two patients and cerebral toxoplasmosis in one). The median CD4 cell count was 238/dl (range 32-1008); 34/59 patients (58%) had a detectable HIV viral load with a median value of 3,400 copies/dl (range 60-455,000) and 36/59 (61%) had received HAART for over three months at the onset of HD.
Fifty-two out of 59 patients (88%) were given HAART concomitantly to Stanford V. Seven patients were not treated antiretrovirally following their physician's decision in five cases and because of the patient's desire in the remaining two cases.
Stanford V was well tolerated and 41/59 patients (69%) completed the treatment plan without any dose reduction or delay in the chemotherapy administration. Toxicity made it necessary for 18 patients (31%) to reduce the dosage of all drugs but Prednisone to 75% or less of the amount they should have been given. The most important dose-limiting side effect was bone marrow toxicity.
Actually, despite the use of G-CSF, 46/59 patients (78%) developed grade 3 and 4 neutropenia (9 and 37 cases, respectively). Grade 3 and 4 anemia was observed in 28/59 patients (47%) (grade 3 in 20 cases and grade 4 in 8 cases), whereas 13/59 patients (22%) showed grade 3 and 4 thrombocytopenia (2 and 11 patients, respectively). Sixteen out of 59 patients (27%) had fever during neutropenia with 5 (8%) documented sepsis. One patient died from septic shock. Four major For personal use only. on October 3, 2017. by guest www.bloodjournal.org From AIDS-defining events were observed during chemotherapy or within one month after this was concluded: tuberculosis in two patients, PCP and wasting syndrome in one patient, respectively. Moreover, 32/59 patients (54%) developed neurotoxicity including grade 2 and 3 constipation (2 and 5 patients, respectively), grade 1 neuromuscular toxicity (4 patients) and grade 2 and 3 neurosensory toxicity (9 and 12 patients, respectively). One patient (2%) suffered from grade 2 hepatic toxicity. No difference in the administration of Stanford V and in the toxic effects was recorded among patients with IPS<2 and those with IPS>2.
We observed also that the underlying HIV infection did not worsen at the end of chemotherapy. After a median follow-up of 17 months, 33/59 patients (56%) are alive and disease-free. The estimated 3-year OS, DFS and FFP are 51% (Figure 1 ), 68% and 60% (Figure 2) , respectively.
Nineteen out of 59 patients (32%) have died: 13 from HD progression, 2 following opportunistic infections and 1 from a treatment-related complication. Three patients have died from different causes, of which two from liver cirrhosis and one, who had primary pulmonary hypertension, from myocardial infarction.
At the univariate analysis the risk group for HIV infection, the presence of B symptoms and an IPS > 2 were associated with a shorter survival. However, the multivariate analysis showed IPS > 2 (HR = 5.8, 95% CI 1.0-33.4, p = 0.05) was the only parameter associated with a significantly shorter survival. In fact, the median of OS was significantly shorter in patients with IPS>2 than in those with IPS <2 (23 months vs. not reached). The probability of OS was significantly (p=0.001) higher among patients with an international prognostic score (IPS) of 2 than in those with IPS >2, and the percentage of OS at three years were 76% and 33% respectively (Figure 3) . Similarly, probability of FFP was significant different (p=0.02), and the percentage of FFP at three years were 83% and 41% respectively for IPS 2 and IPS>2 (Figure 4) .
DISCUSSION
This is the largest prospective study ever performed in patients with HD-HIV treated with concomitant aggressive chemotherapy and HAART. The baseline findings of our patients are similar to those reported by previous prospective studies both for HD characteristics (i.e. histological subtypes, advanced stage, B-symptoms and extranodal involvement) and HIV infection (i.e. median CD4 cell count, previous diagnosis of AIDS).
The results of our study show such an approach is feasible, with only one treatment-related toxic death reported. Myelosuppression and neurotoxicity are the most important dose-limiting side effects. Indeed, the incidence of grade 3-4 neutropenia, anemia and thrombocytopenia are 78%, 47% and 22%, respectively, whereas 29% of our patients experienced grade 3 neurotoxicity.
The high incidence of bone marrow suppression in the present study can be related to the dose intensity of Stanford V and to the concomitant use of HAART, which included myelotoxic drugs.
Eleven out of 52 ( 21%) patients used zidovudine and 35/52 (67%) patients took lamivudine as part of their HAART during the administration of Stanford V. Similarly, the high incidence of neurotoxicity can be ascribed to the HAART regimen including a neurotoxic drug (didanosine, zalcitabine and stavudine) in 43/52 (83%) of our patients.
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Moreover, the incidence of OI during chemotherapy or within 3 months of its completion is significantly lower in our study (7%) than in the ABVD study (29%) of the ACTG trial. This can be explained only in part with the higher median CD4 cell count of our patients (238/dl) as compared to the patients treated with ABVD (113/dl), even though we feel the concomitant use of HAART and chemotherapy is the most important factor for the decrease in OIs. Interestingly, the incidence of neutropenia is similar to the rate reported by Horning et al who administered Stanford V in the general population, even if anemia and thrombocytopenia are recorded more often in the HIV setting, which may be due to the use of HAART and to HIV-related myelodisplasia.
We observed also grade 3 neurotoxicity in 29% of the cases, which is similar to the rate reported with Stanford V on the general population (35%).
The comparison of our study with the previous prospective studies published so far in the HIV setting shows CR, DFS and OS rates improve significantly. In our study 81% of the patients achieved CR vs. 74% in our previous EBVP study and 43% in the ABVD study. Median OS is 16 and 18 months, respectively, for the patients treated with EVBP and ABVD, whereas it has not been reached in the present study with an estimated 3-year OS of 51%. Moreover, the 3-year DFS of our study is significantly better than that observed with EBVP (53%) and ABVD (median duration 13 months). Whether the better survival rate is related or not to a decrease in the number of AIDSrelated deaths after the introduction of HAART in the management of HIV patients, it seems clear that the longer DFS is related to the more effective chemotherapy employed. However, we think that, just as seen in our study patients with HIV-related non-Hodgkin's lymphoma, the use of HAART during and after chemotherapy could prolong the duration of CR (18) .
In the general population, the use of the Stanford V regimen has been associated with a 5-year FFP and OS of 89% and 96%, respectively (10) . As expected, the outcome of our patients was worse 
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*According to Hasenclever and Diehl
